

Fabio Stagno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6198527/publications.pdf>

Version: 2024-02-01

213
papers

4,048
citations

117625

34
h-index

149698

56
g-index

213
all docs

213
docs citations

213
times ranked

4175
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	6.3	362
2	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. <i>Blood</i> , 2009, 114, 4933-4938.	1.4	203
3	Age and d<sc>PCR</sc> can predict relapse in <sc>CML</sc> patients who discontinued imatinib: The <sc>ISAV</sc> study. <i>American Journal of Hematology</i> , 2015, 90, 910-914.	4.1	181
4	Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. <i>Leukemia</i> , 2013, 27, 1511-1519.	7.2	119
5	Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. <i>Leukemia</i> , 2001, 15, 976-980.	7.2	80
6	Nuclear Translocation of Heme Oxygenase-1 Confers Resistance to Imatinib in Chronic Myeloid Leukemia Cells. <i>Current Pharmaceutical Design</i> , 2013, 19, 2765-2770.	1.9	80
7	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , 2015, 29, 1823-1831.	7.2	77
8	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009, 94, 205-212.	3.5	73
9	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
10	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients. <i>PLoS ONE</i> , 2014, 9, e101848.	2.5	71
11	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. <i>Nature Communications</i> , 2018, 9, 2192.	12.8	66
12	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	5.2	66
13	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	2.8	63
14	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	1.4	61
15	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009, 113, 3428-3434.	1.4	59
16	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013, 31, 103-109.	1.7	59
17	Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1085-1098.	4.1	59
18	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011, 96, 1457-1461.	3.5	58

#	ARTICLE	IF	CITATIONS
19	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	3.5	58
20	Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. <i>Leukemia Research</i> , 2004, 28, 469-477.	0.8	57
21	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015, 39, 1055-1059.	0.8	57
22	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	7.2	57
23	Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 273-278.	2.4	54
24	Management of Chronic Myeloid Leukemia in Advanced Phase. <i>Frontiers in Oncology</i> , 2019, 9, 1132.	2.8	54
25	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomyacin B. <i>Blood</i> , 2006, 107, 1591-1598.	1.4	53
26	Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia. <i>Molecular Cancer</i> , 2018, 17, 56.	19.2	53
27	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	1.7	53
28	Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. <i>Acta Oncologica</i> , 2010, 49, 506-508.	1.8	51
29	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 5138-5144.	1.4	49
30	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019, 12, 131.	17.0	45
31	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013, 98, 399-403.	3.5	42
32	Effects of imatinib mesylate in osteoblastogenesis. <i>Experimental Hematology</i> , 2009, 37, 461-468.	0.4	41
33	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1146-1150.	3.5	39
34	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	2.7	36
35	Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 1070-1080.	3.6	36
36	Multidrug resistance mechanisms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 116, 774-780.	2.5	35

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	7.2	35
38	BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint. <i>Acta Haematologica</i> , 2011, 126, 205-210.	1.4	34
39	High <i>BCR-ABL/GUSIS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib. <i>Clinical Cancer Research</i> , 2017, 23, 7189-7198.	7.0	34
40	IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. <i>Carcinogenesis</i> , 2014, 35, 1132-1143.	2.8	33
41	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	1.8	32
42	Survivin expression in chronic myeloid leukemia. <i>Cancer Letters</i> , 2005, 225, 105-110.	7.2	31
43	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.8	30
44	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. <i>PLoS ONE</i> , 2016, 11, e0158392.	2.5	30
45	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	5.0	30
46	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. <i>Blood Cancer Journal</i> , 2015, 5, e347-e347.	6.2	29
47	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011, 35, 1164-1169.	0.8	28
48	A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. <i>American Journal of Hematology</i> , 2017, 92, 82-87.	4.1	27
49	Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. <i>Hematological Oncology</i> , 2012, 30, 27-33.	1.7	26
50	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	4.1	26
51	Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	5.3	24
52	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	1.8	24
53	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016, 101, 1200-1207.	3.5	22
54	Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. <i>Cancer</i> , 2018, 124, 2228-2237.	4.1	22

#	ARTICLE	IF	CITATIONS
55	Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53. <i>Frontiers in Oncology</i> , 2019, 9, 57.	2.8	22
56	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	1.7	21
57	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. <i>Cancers</i> , 2021, 13, 1311.	3.7	21
58	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	2.5	20
59	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	1.7	19
60	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008, 112, 181-181.	1.4	19
61	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 211-219.	1.8	18
62	Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 883.	2.8	18
63	BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.. <i>Blood</i> , 2010, 116, 3426-3426.	1.4	18
64	Role of interferon regulatory factor 1 in monocyte/macrophage differentiation. <i>European Journal of Immunology</i> , 1999, 29, 3009-3016.	2.9	17
65	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	1.8	17
66	Hyperdiploidy Associated with a High BCR-ABL Transcript Level May Identify Patients at Risk of Progression in Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2012, 127, 7-9.	1.4	16
67	Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2226.	4.1	16
68	Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients. <i>British Journal of Haematology</i> , 2012, 159, 237-240.	2.5	15
69	SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. <i>BMC Cancer</i> , 2013, 13, 60.	2.6	15
70	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	3.5	15
71	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014, 89, 119-124.	4.1	14
72	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e497.	2.7	14

#	ARTICLE	IF	CITATIONS
73	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	1.8	14
74	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010, 116, 359-359.	1.4	14
75	The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. <i>Blood</i> , 2012, 120, 1678-1678.	1.4	14
76	Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. <i>Leukemia Research</i> , 2008, 32, 673-674.	0.8	13
77	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. <i>American Journal of Hematology</i> , 2010, 85, 960-963.	4.1	13
78	Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22). <i>Anticancer Research</i> , 2019, 39, 3893-3899.	1.1	13
79	B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 <i>BCR-ABL</i> Transcripts: A Case Report. <i>Anticancer Research</i> , 2019, 39, 431-435.	1.1	13
80	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. <i>Blood</i> , 2020, 136, 2237-2240.	1.4	13
81	Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019, 134, 496-496.	1.4	13
82	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 179-183.	1.8	12
83	BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2019, 9, 764.	2.8	12
84	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3â€year followâ€up. <i>American Journal of Hematology</i> , 2010, 85, 375-377.	4.1	10
85	Rotation of nilotinib and imatinib for firstâ€line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 617-622.	4.1	10
86	Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report. <i>Anticancer Research</i> , 2019, 39, 3949-3954.	1.1	10
87	Colony-Forming Cell Assay Detecting the Co-Expression of <i>JAK2</i> and <i>V617F</i> and <i>BCR-ABL1</i> in the Same Clone: A Case Report. <i>Acta Haematologica</i> , 2019, 141, 261-267.	1.4	10
88	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	1.3	10
89	Clinical Relevance of ABCB1, ABCC2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib. <i>Frontiers in Oncology</i> , 2021, 11, 672287.	2.8	10
90	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016, 128, 3070-3070.	1.4	10

#	ARTICLE	IF	CITATIONS
91	Hypereosinophilia and subcutaneous heparin. <i>Lancet</i> , The, 1993, 342, 1371.	13.7	9
92	CD34 Expression in Adult Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1995, 18, 31-36.	1.3	9
93	Evaluation of taxol cytotoxicity on B-CLL cells in vitro. <i>Leukemia and Lymphoma</i> , 1997, 26, 115-119.	1.3	9
94	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	1.8	9
95	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTiMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	2.8	9
96	Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib. <i>In Vivo</i> , 2019, 33, 1593-1598.	1.3	8
97	Imatinib Suspension and Validation (ISAV) Study: Final Results at 79 Months. <i>Blood</i> , 2018, 132, 461-461.	1.4	8
98	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	1.4	8
99	Aberrant Phenotypic Expression of the T-Cell-Associated Antigen CD8 on B-Cell Chronic Lymphocytic Leukemia Cells. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2009, 15, 1-3.	1.2	8
100	Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2011, 86, 523-525.	4.1	7
101	TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019025.	1.3	7
102	The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6106.	4.1	7
103	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). <i>Blood</i> , 2011, 118, 2756-2756.	1.4	7
104	Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. <i>European Journal of Haematology</i> , 2011, 86, 216-225.	2.2	6
105	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.8	6
106	Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a cml patient expressing a rare e14a3 bcr-abl1 fusion transcript: A case report. <i>Oncology Letters</i> , 2019, 18, 2648-2653.	1.8	6
107	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	6.2	6
108	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	2.8	6

#	ARTICLE	IF	CITATIONS
109	Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells. <i>Journal of Clinical Medicine</i> , 2021, 10, 5606.	2.4	6
110	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Frontiers in Oncology</i> , 2022, 12, 835563.	2.8	6
111	All-Trans-Retinoic-Acid- and Growth-Factor- Mediated Induction of Alkaline Phosphatase Activity in Freshly Isolated Chronic Myeloid Leukemia Cells. <i>Acta Haematologica</i> , 1999, 102, 61-65.	1.4	5
112	Uncommon long-term survival in a patient with chronic myeloid leukemia. <i>Acta Oncologica</i> , 2009, 48, 1215-1216.	1.8	5
113	Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain. <i>Leukemia Research</i> , 2009, 33, e157-e158.	0.8	5
114	Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias. <i>Acta Oncologica</i> , 2010, 49, 111-112.	1.8	5
115	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. <i>Blood</i> , 2019, 134, 661-661.	1.4	5
116	The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2012, 120, 1680-1680.	1.4	5
117	Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. <i>Blood</i> , 2012, 120, 3784-3784.	1.4	5
118	Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). <i>Blood</i> , 2014, 124, 1806-1806.	1.4	5
119	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. <i>Blood</i> , 2011, 118, 786-786.	1.4	5
120	Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate. <i>European Journal of Haematology</i> , 2004, 73, 147-148.	2.2	4
121	Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. <i>Leukemia Research</i> , 2010, 34, e224-e225.	0.8	4
122	Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients. <i>Anticancer Research</i> , 2020, 40, 5313-5317.	1.1	4
123	On the road to treatment-free remission in chronic myeloid leukemia: what about "the others"? Expert Review of Anticancer Therapy, 2020, 20, 1075-1081.	2.4	4
124	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 271-279.	2.5	4
125	Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. <i>Blood</i> , 2018, 132, 45-45.	1.4	4
126	High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib. <i>Blood</i> , 2013, 122, 1495-1495.	1.4	4

#	ARTICLE	IF	CITATIONS
127	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. <i>Blood</i> , 2014, 124, 813-813.	1.4	4
128	Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myeloid Leukemia: Comparison with FISH and PCR Techniques. <i>PLoS ONE</i> , 2015, 10, e0130360.	2.5	4
129	Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection. <i>Cancers</i> , 2022, 14, 1173.	3.7	4
130	In vitro Apoptotic Response of Freshly Isolated Chronic Myeloid Leukemia Cells to all-trans Retinoic Acid and Cytosine Arabinoside. <i>Acta Haematologica</i> , 2000, 104, 57-64.	1.4	3
131	Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase. <i>Leukemia Research</i> , 2009, 33, e17.	0.8	3
132	Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?. <i>Lancet Oncology</i> , The, 2011, 12, 118.	10.7	3
133	Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment. <i>Leukemia Research</i> , 2012, 36, 1208-1209.	0.8	3
134	Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 803.	0.8	3
135	Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report. <i>In Vivo</i> , 2020, 34, 1481-1486.	1.3	3
136	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , 2021, 35, 1814-1816.	7.2	3
137	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.	1.4	3
138	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018, 132, 458-458.	1.4	3
139	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. <i>Blood</i> , 2019, 134, 4145-4145.	1.4	3
140	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009, 114, 860-860.	1.4	3
141	High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.. <i>Blood</i> , 2012, 120, 2790-2790.	1.4	3
142	Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib. <i>Blood</i> , 2015, 126, 2767-2767.	1.4	3
143	Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. <i>Blood</i> , 2015, 126, 2775-2775.	1.4	3
144	Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. <i>Diagnostics</i> , 2022, 12, 1051.	2.6	3

#	ARTICLE	IF	CITATIONS
145	Indagine Sui Vegetali Causa di Degrado dei Monumenti Della Citta' di Noto (Sicilia Orientale). Giornale Botanico Italiano (Florence, Italy: 1962), 1996, 130, 457-457.	0.0	2
146	Infliximab therapy in hematologic malignancies: handle with care (Comment). Haematologica, 2012, 97, e26-e26.	3.5	2
147	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. Acta Oncologica, 2021, 60, 1527-1533.	1.8	2
148	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. Blood, 2019, 134, 29-29.	1.4	2
149	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. Blood, 2020, 136, 43-44.	1.4	2
150	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. Blood, 2010, 116, 2471-2471.	1.4	2
151	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. Blood, 2013, 122, 258-258.	1.4	2
152	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. Blood, 2015, 126, 2792-2792.	1.4	2
153	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. Blood, 2010, 116, 1230-1230.	1.4	2
154	Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. Blood, 2012, 120, 2797-2797.	1.4	2
155	Successful Healing of Hydroxyurea-Related Leg Ulcers With Topical Granulocyte-Macrophage Colony-Stimulating Factor. Blood, 1999, 94, 1479-1480.	1.4	2
156	A Treatment-free Interval Allowed by Ponatinib as Fourth-line Therapy. Cancer Diagnosis & Prognosis, 2021, 1, 19-22.	0.7	2
157	Successful Treatment of Granulocytic Sarcoma with Î±-Interferon and Disodium Pamidronate at Presentation of Chronic Myeloid Leukemia. Acta Haematologica, 2001, 105, 116-117.	1.4	1
158	VLA-2 and VLA-5 Cell Adhesion Molecules Expression in CD34+ Cells from Umbilical Cord Blood and from Bone Marrow. Blood Purification, 2002, 20, 174-176.	1.8	1
159	T Cell Receptor Î³-Chain Gene Rearrangement in a Novel Case of Adult NK Cell Leukemia. Acta Haematologica, 2004, 111, 225-227.	1.4	1
160	Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy. International Journal of Hematology, 2012, 96, 142-143.	1.6	1
161	Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S313-S314.	0.4	1
162	A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic. Diagnostics, 2021, 11, 1502.	2.6	1

#	ARTICLE	IF	CITATIONS
163	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	5.0	1
164	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. <i>Blood</i> , 2018, 132, 3006-3006.	1.4	1
165	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , 2018, 132, 3012-3012.	1.4	1
166	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018, 132, 1732-1732.	1.4	1
167	A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity. <i>Blood</i> , 2019, 134, 4141-4141.	1.4	1
168	CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2007, 110, 4672-4672.	1.4	1
169	T/NK Lymphocytosis in CML Ph+ Patients During Dasatinib Therapy.. <i>Blood</i> , 2009, 114, 3279-3279.	1.4	1
170	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. <i>Blood</i> , 2011, 118, 2770-2770.	1.4	1
171	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. <i>Blood</i> , 2011, 118, 453-453.	1.4	1
172	High BCR-ABL/GUSIS Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib. <i>Blood</i> , 2015, 126, 4049-4049.	1.4	1
173	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. <i>Blood</i> , 2016, 128, 3068-3068.	1.4	1
174	Role of Imatinib Mesylate in Osteoblastogenesis.. <i>Blood</i> , 2007, 110, 1928-1928.	1.4	1
175	Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 European Leukemia Net (ELN) Criteria.. <i>Blood</i> , 2009, 114, 3302-3302.	1.4	1
176	Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. <i>Blood</i> , 2010, 116, 2294-2294.	1.4	1
177	Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elderly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. <i>Blood</i> , 2011, 118, 2751-2751.	1.4	1
178	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	1
179	Botaniche Applicate. <i>Giornale Botanico Italiano</i> (Florence, Italy: 1962), 1995, 129, 48-63.	0.0	0
180	Utility of Flow Cytometry as a Screening Tool for Transplant Donors for Chronic Lymphocytic Leukemia. <i>Acta Haematologica</i> , 2010, 123, 235-236.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia. Acta Haematologica, 2010, 124, 103-104.	1.4	0
182	Diagnosis of Blastic Phase of Chronic Myeloid Leukemia. Acta Haematologica, 2012, 127, 198-198.	1.4	0
183	Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013;121(26):5138-5144.. Blood, 2014, 123, 2902-2902.	1.4	0
184	Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the 'NEXT-IN-CML' Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S310-S311.	0.4	0
185	Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e456-e459.	0.4	0
186	In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.. Blood, 2006, 108, 4981-4981.	1.4	0
187	Hypoxia Induces Imatinib Resistance in CML Cell Lines.. Blood, 2006, 108, 4387-4387.	1.4	0
188	Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. Blood, 2007, 110, 4564-4564.	1.4	0
189	Abstract 1805: Improving on Imatinib for targeted therapy of chronic myeloid leukemia: First line treatment with Nilotinib 800 mg daily results in unprecedentedly high rate of rapid, 'deep' and stable molecular responses - Results of a phase 2 trial of the GIMEMA CML working party. , 2010, , .		0
190	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. Blood, 2010, 116, 2270-2270.	1.4	0
191	First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, 'Deep' and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2010, 116, 2720-2720.	1.4	0
192	Mechanisms of Heme Oxygenase 1-Induced Resistance to Imatinib In CML Cells.. Blood, 2010, 116, 3385-3385.	1.4	0
193	Effects of the Second Generation Tyrosin Kinase Inhibitors on Osteogenic Differentiation.. Blood, 2010, 116, 3386-3386.	1.4	0
194	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly ('¥ 65 years) Ph+ CML Patients ' EudraCT Number 2007'005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	1.4	0
195	Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,. Blood, 2011, 118, 3766-3766.	1.4	0
196	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. Blood, 2011, 118, 1682-1682.	1.4	0
197	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. Blood, 2011, 118, 1686-1686.	1.4	0
198	Myeloid-Derived Suppressor Cells Increase in Chronic Myeloid Leukemia and Exert Immune Suppressive Activity.. Blood, 2012, 120, 2779-2779.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. <i>Blood</i> , 2012, 120, 4234-4234.	1.4	0
200	Validation of Digital-PCR Analysis through Programmed imatinib Interruption in Q-RT-PCR Negative Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 4040-4040.	1.4	0
201	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis. <i>Blood</i> , 2013, 122, 2711-2711.	1.4	0
202	The importance of comorbidity and the usefulness of therapeutic early shift in the management of CML patients. <i>Clinical Management Issues</i> , 2011, 5, 3-4.	0.3	0
203	Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib. <i>Clinical Management Issues</i> , 2010, 4, 7-11.	0.3	0
204	Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients. <i>Blood</i> , 2015, 126, 4018-4018.	1.4	0
205	Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. <i>Blood</i> , 2015, 126, 4046-4046.	1.4	0
206	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. <i>Blood</i> , 2016, 128, 3076-3076.	1.4	0
207	Abstract 1134: The tumor suppressor activity of miR-300 is detrimental for leukemia development but required for leukemia stem cell maintenance. , 2018, , .		0
208	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438.	1.4	0
209	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021.	1.4	0
210	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. <i>Blood</i> , 2018, 132, 4251-4251.	1.4	0
211	Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients. <i>Blood</i> , 2019, 134, 1714-1714.	1.4	0
212	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	1.4	0
213	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	1.4	0